Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome

Table 3 Comparison of survivors and non-survivors at 28 d

Characteristics	28-d mortality
	Yes (n = 19)	No (n = 31)	P value
Age (yr)	45 ± 121	47 ± 14	0.649
Male gender	16 (84)2	27 (87)	1.000
Prior decompensation	11 (57.9)	17 (54.8)	0.833
Bilirubin (mg/dL)	17.7 (1.2-37.6)3	10.7 (0.6-43.0)	0.139
Total leukocyte count (/mm3)	11200 (2700-39000)	9300 (3600-36400)	0.873
Platelet count (103/mm3)	81.0 (14.8-382.0)	90.0 (14.4-444.0)	0.734
International normalized ratio	2.7 ± 0.7	2.3 ± 0.8	0.054
Serum creatinine (mg/dL)	2.2 (0.5-7.9)	1.6 (0.6-6.3)	0.509
Jaundice	18 (95)	27 (87)	0.637
Ascites	17 (90)	25 (81)	0.693
Hepatic encephalopathy	10 (53)	7 (23)	0.037
Upper gastrointestinal bleed	1 (5)	5 (16)	0.387
Organ failures
Liver	14 (74)	15 (48)	0.139
Kidney	12 (63)	10 (32)	0.033
Cerebral	5 (26)	0 (0)	0.005
Coagulation	12 (63)	11 (36)	0.057
Respiratory	0 (0)	2 (11)	0.140
Circulation	1 (5)	1 (5)	1.000
Prognostic scores
Child-Pugh score	12.3 ± 1.3	10.8 ± 1.7	0.002
MELD score	32.8 ± 7.1	27.1 ± 7.5	0.010
APACHE II score	15.0 (8-41)	10.0 (4.0-25.0)	0.001
CLIF-SOFA score	11.6 ± 2.5	8.8 ± 2.3	< 0.001

¹mean ± SD;

²Number (percentage);

³Median (range). ACLF: Acute-on-Chronic Liver Failure; APACHE: Acute Physiology and Chronic Health Evaluation; APASL: Asia-Pacific Association for the Study of Liver; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; MELD: Model for End-stage Liver Disease.